329 related articles for article (PubMed ID: 15728186)
21. Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients.
Nakazawa S; Imamura R; Kawamura M; Kato T; Abe T; Namba T; Iwatani H; Yamanaka K; Uemura M; Kishikawa H; Nishimura K; Oka K; Tajiri M; Wada Y; Nonomura N
Biochem Biophys Res Commun; 2019 Jan; 508(4):1106-1112. PubMed ID: 30553446
[TBL] [Abstract][Full Text] [Related]
22. IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2.
Stewart TJ; Takahashi K; Whitaker RH; Raska M; Placzek WJ; Novak J; Renfrow MB
Glycobiology; 2019 Jul; 29(7):543-556. PubMed ID: 30759204
[TBL] [Abstract][Full Text] [Related]
23. Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy.
Narita I; Gejyo F
Clin Exp Nephrol; 2008 Oct; 12(5):332-338. PubMed ID: 18404247
[TBL] [Abstract][Full Text] [Related]
24. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.
Yu G; Zhang Y; Meng B; Xie X; Wang Z; Ying W; Lv J; Zhang H
Nephrol Dial Transplant; 2021 Dec; 37(1):33-41. PubMed ID: 34152412
[TBL] [Abstract][Full Text] [Related]
25. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy.
Barratt J; Smith AC; Feehally J
Nephrology (Carlton); 2007 Jun; 12(3):275-84. PubMed ID: 17498123
[TBL] [Abstract][Full Text] [Related]
26. Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum.
Iwanami N; Iwase H; Takahashi N; Kato K; Itoh A; Takatani T; Makita S; Kobayashi Y; Okamoto M; Nakamura S; Hiki Y; Ishii M
J Nephrol; 2008; 21(1):118-26. PubMed ID: 18264945
[TBL] [Abstract][Full Text] [Related]
27. Aberrant glycosylation in IgA nephropathy (IgAN).
Coppo R; Amore A
Kidney Int; 2004 May; 65(5):1544-7. PubMed ID: 15086888
[TBL] [Abstract][Full Text] [Related]
28. Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy.
Allen AC
J Nephrol; 1999; 12(2):76-84. PubMed ID: 10378662
[TBL] [Abstract][Full Text] [Related]
29. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Hiki Y; Tanaka A; Kokubo T; Iwase H; Nishikido J; Hotta K; Kobayashi Y
J Am Soc Nephrol; 1998 Apr; 9(4):577-82. PubMed ID: 9555659
[TBL] [Abstract][Full Text] [Related]
30. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.
Novak J; Julian BA; Tomana M; Mestecky J
Semin Nephrol; 2008 Jan; 28(1):78-87. PubMed ID: 18222349
[TBL] [Abstract][Full Text] [Related]
31. O-linked glycosylation determines the nephritogenic potential of IgA rheumatoid factor.
Kihara M; Ito K; Nakata J; Otani M; Tran NL; Morito N; Takahashi S; Wada Y; Izui S
J Am Soc Nephrol; 2014 Jun; 25(6):1282-90. PubMed ID: 24511137
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of IgA1 O-glycosylation in Henoch-Schönlein Purpura Nephritis Using Mass Spectrometry.
Nakazawa S; Imamura R; Kawamura M; Kato T; Abe T; Iwatani H; Yamanaka K; Uemura M; Kishikawa H; Nishimura K; Tajiri M; Wada Y; Nonomura N
Transplant Proc; 2019 Jun; 51(5):1481-1487. PubMed ID: 31084922
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Potential of Plasma IgA1 O-Glycans in Discriminating IgA Nephropathy From Other Glomerular Diseases and Healthy Participants.
Zhang S; Sun H; Zhang Z; Li M; Guo Z; Ye W; Cai G; Sun W; Li M
Front Mol Biosci; 2022; 9():871615. PubMed ID: 35445079
[No Abstract] [Full Text] [Related]
34. Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS.
Klapoetke SC; Zhang J; Becht S
J Pharm Biomed Anal; 2011 Nov; 56(3):513-20. PubMed ID: 21752569
[TBL] [Abstract][Full Text] [Related]
35. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
Stuchlova Horynova M; Vrablikova A; Stewart TJ; Takahashi K; Czernekova L; Yamada K; Suzuki H; Julian BA; Renfrow MB; Novak J; Raska M
Nephrol Dial Transplant; 2015 Feb; 30(2):234-8. PubMed ID: 25281698
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the specific structures of IgA1 hinge glycopeptide in 30 IgA nephropathy patients by mass spectrometry.
Odani H; Yamamoto K; Iwayama S; Iwase H; Takasaki A; Takahashi K; Fujita Y; Sugiyama S; Hiki Y
J Nephrol; 2010; 23(1):70-6. PubMed ID: 20091489
[TBL] [Abstract][Full Text] [Related]
37. The nucleotide sequence of the IgA1 hinge region in IgA nephropathy.
Greer MR; Barratt J; Harper SJ; Allen AC; Feehally J
Nephrol Dial Transplant; 1998 Aug; 13(8):1980-3. PubMed ID: 9719151
[TBL] [Abstract][Full Text] [Related]
38. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry.
Odani H; Hiki Y; Takahashi M; Nishimoto A; Yasuda Y; Iwase H; Shinzato T; Maeda K
Biochem Biophys Res Commun; 2000 Apr; 271(1):268-74. PubMed ID: 10777713
[TBL] [Abstract][Full Text] [Related]
39. Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy?
Leung JC; Poon PY; Lai KN
J Lab Clin Med; 1999 Feb; 133(2):152-60. PubMed ID: 9989767
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients.
Kosztyu P; Hill M; Jemelkova J; Czernekova L; Kafkova LR; Hruby M; Matousovic K; Vondrak K; Zadrazil J; Sterzl I; Mestecky J; Raska M
Kidney Blood Press Res; 2018; 43(2):350-359. PubMed ID: 29529610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
